

MedDRA - Terminologies & Coding

Dr Anamika Dutta Medical Officer, MedDRA MSSO 6th Asia Pacific Pharmacovigilance Training Course Feb 26th 2020







Disclaimer and Copyright Notice

- This presentation is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.



Coding?



What is Coding ?





Why code?



How does this look to you?





What do you see?






MedDRA What is MedDRA?

Med = Medical

D = Dictionary for

R = Regulatory

A = Activities



MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from premarketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.



MedDRA Data Sharing


- Subscription grants access to MedDRA for one year
- Subscriber cannot grant any sublicense, publish or otherwise distribute MedDRA to a third party
- Data may be freely exchanged between current MedDRA subscribers
 - -Sponsor-sponsor, sponsor-CRO, vendor-user, etc.
 - Use Self-Service Application to check organization's subscription status
- Sharing MedDRA with a non-subscribing organization is a violation of the MedDRA license



2019 MedDRA Subscription Rate Table


MedDRA Subscription Types	2019 Annual Subscription Rates
Regulatory Authority	\$0 USD
Non-Commercial / Non-Profit	\$0 USD
Commercial (Parent Company Annual Revenue or Turnover)	
Level 0 (Annual Revenue < \$1 Million)	\$154 USD
Level 1 (Annual Revenue \$1-\$10 Million)	\$654 USD
Level 2 (Annual Revenue \$10-\$20 Million)	\$2,496 USD
Level 3 (Annual Revenue \$20-\$500 Million)	\$4,727 USD
Level 4 (Annual Revenue \$500 Million-\$1 Billion)	\$9,918 USD
Level 5 (Annual Revenue \$1-\$5 Billion)	\$41,150 USD
Level 6 (Annual Revenue \$5-\$20 Billion)	\$54,334 USD
Level 7 (Annual Revenue > \$20 Billion)	\$70,889 USD
System Developer	\$2,556 USD

77% of all MedDRA users pay no fee or \$654 (or less)





How to subscribe?



Phone: *

Country: *



Scope of MedDRA

Not a drug dictionary

Patient demographic terms

Clinical trial study design terms

OUT

IN

Frequency qualifiers

Medical conditions
Indications
Investigations (tests, results)
Medical and surgical procedures
Medical, social, family history
Medication errors
Product quality issues
Device-related issues
Product use issues
Pharmacogenetic terms
Toxicologic issues
Standardized queries

Numerical values for results

Severity descriptors

Not an equipment, device, diagnostic product dictionary



MedDRA MedDRA Structure

System Organ Class (SOC) (27)

High Level Group Term (HLGT) (337)

High Level Term (HLT) (1,737)

Preferred Term (PT) (23,708)

Lowest Level Term (LLT) (80,262)



System Organ Classes


- Blood and lymphatic system disorders
- Cardiac disorders
- Congenital, familial and genetic disorders
- Ear and labyrinth disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal disorders
- General disorders and administration site conditions
- Hepatobiliary disorders
- Immune system disorders
- Infections and infestations
- Injury, poisoning and procedural complications
- Investigations
- Metabolism and nutrition disorders

- Musculoskeletal and connective tissue disorders
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Nervous system disorders
- Pregnancy, puerperium and perinatal conditions
- Product issues
- Psychiatric disorders
- Renal and urinary disorders
- Reproductive system and breast disorders
- Respiratory, thoracic and mediastinal disorders
- Skin and subcutaneous tissue disorders
- Social circumstances
- Surgical and medical procedures
- Vascular disorders



Lowest Level Term

Synonyms, lexical variants, sub-elements






Non-Current Terms

- Flagged at the LLT level in MedDRA
- Not recommended for continued use
- Retained to preserve historical data for retrieval and analysis
- Terms that are vague, ambiguous, outdated, truncated, or misspelled
- Terms derived from other terminologies that do not fit MedDRA rules



MedDRA Codes and Languages





MedDRA A Multi-Axial Terminology

- Multi-axial = the representation of a medical concept in multiple SOCs
 - Allows grouping by different classifications
 - -Allows retrieval and presentation via different data sets
- All PTs assigned a primary SOC
 - Determines which SOC will represent a PT during cumulative data outputs
 - –Prevents "double counting"
 - -Supports standardized data presentation
 - Pre-defined allocations should not be changed by users



A Multi-Axial Terminology (cont)

SOC = Respiratory, thoracic and mediastinal disorders (Secondary SOC)



HLGT = Respiratory tract infections



HLT = Viral upper respiratory tract infections



PT = Influenza

SOC = Infections and infestations (Primary SOC)



HLGT = Viral infectious disorders



HLT = Influenza viral infections





What are coding conventions?





MedDRA ICH MedDRA Coding Guide

MedDRA Term Selection: Points to Consider (MTS:PTC)

MedDRA® TERM SELECTION: POINTS TO CONSIDER

ICH-Endorsed Guide for MedDRA Users

Release 4.17 Based on MedDRA Version 22.0

1 March 2019

Disclaimer and Copyright Notice

This document is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.

The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.

The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

MedDRA® trademark is registered by IFPMA on behalf of ICH

- Provides term selection advice for industry and regulatory purposes
- Objective is to promote accurate and consistent term selection to facilitate a common understanding of shared data
- Recommended to be used as basis for individual organization's own coding conventions



General Term Selection Principles

- Quality of Source Data
- Quality Assurance
- Do Not Alter MedDRA
- Always Select a Lowest Level Term
- Select Only Current Lowest Level Terms
- When to Request a Term
- Use of Medical Judgment in Term Selection
- Selecting More than One Term
- Check the Hierarchy
- Select Terms for All Reported Information, Do Not Add Information



Term Selection Points

- Diagnoses and Provisional Diagnoses with or without Signs and Symptoms
- Death and Other Patient Outcomes
- Suicide and Self-Harm
- Conflicting/Ambiguous/Vague Information
- Combination Terms
- Age vs. Event Specificity
- Body Site vs. Event Specificity
- Location-Specific vs. Microorganism-Specific Information
- Modification of Pre-existing Conditions
- Exposures During Pregnancy and Breast Feeding
- Congenital Terms
- Neoplasms
- Medical and Surgical Procedures
- Investigations



Term Selection Points (cont)

- Medication Errors, Accidental Exposures and Occupational Exposures
- Misuse, Abuse and Addiction
- Transmission of Infectious Agent via Product
- Overdose, Toxicity and Poisoning
- Device-related Terms
- Drug Interactions
- No Adverse Effect and "Normal" Terms
- Unexpected Therapeutic Effect
- Modification of Effect
- Social Circumstances
- Medical and Social History
- Indication for Product Use
- Off Label Use
- Product Quality Issues





MedDRA Some Points to consider

- Obtain clarification of data that are ambiguous, confusing, or unintelligible
- Do Not Alter MedDRA: Users must not make ad hoc structural alterations, including changing the primary SOC allocation
- Avoid company-specific "work-arounds" for MedDRA deficiencies, submit change request to MSSO
- Select current LLTs only
 - Non-current terms for legacy conversion/historical purposes



MedDRA Some Points to consider

- Lowest Level Term that most accurately reflects the reported verbatim information should be selected
- Degree of specificity may be challenging
 - -Example: "Abscess on face" → select "Facial abscess," not simply "Abscess"
- If no exact match in MedDRA, use medical judgment to match to an existing term that adequately represents the concept
- Check the hierarchy above a selected LLT (PT, HLT, HLGT, SOC) to ensure placement accurately reflects meaning of reported term




MedDRA Some Points to consider

- Can select more than one LLT to represent reported information. Document procedures.
- Select terms for every AR/AE reported, regardless of causal association
- Select terms for device-related events, product quality issues, medication errors, medical and social history, investigations and indications as appropriate
- Do not make diagnosis if only signs/symptoms reported



MedDRA Browser & Demonstration






MSSO's MedDRA Browsers

- MedDRA Desktop Browser (MDB)
 - Download MDB and release files from MedDRA website
- MedDRA Web-Based Browser (WBB)
 - https://tools.meddra.org/wbb/
- Features
 - -Both require MedDRA ID and password
 - -View/search MedDRA and SMQs
 - Support for all MedDRA languages
 - Language specific interface
 - Ability to export search results and Research Bin to local file system



Assessing the Reported Information

- Consider what is being reported. Is it a:
 - Clinical condition Diagnosis, sign or symptom?
 - Indication?
 - Test result?
 - Injury?
 - Procedure?
 - Medication error?
 - Product use issue?
 - Product quality issue?
 - Social circumstance?
 - Device issue?
 - Procedural complication?
 - Is it a combination of these?





Specificity

The patient suffered from an <u>allergic reaction to an</u> <u>antibiotic</u>





Symptoms

The patient states she has been experiencing <u>cold</u> <u>sweats</u>





Investigations

Lab results indicate the patient has <u>increased</u> troponin and increased CPK-MB





Patient demographics

A 2 day old <u>baby</u> was noted to have a mild <u>fever</u>





Indications

A 35 year old woman was taking Drug X to <u>prevent</u> relapses of <u>multiple sclerosis</u>





Product quality issues

It was determined that the product was counterfeit





Social circumstances

The patient was confined to a wheelchair





Medication errors/Product use errors and issues

The pharmacist made a <u>mistake in compounding</u> the medication





MedDRA Coding Exercise





Verbatim: "Man with decreased fertility."

- A. Infertility
- B. Fertility decreased male
- C. Infertility male
- D. Fertility decreased



Verbatim: "Became color blind in adolescence"

- A. Color blindness
- B. Blindness color
- C. Colour blindness acquired
- D. Color blindness acquired



Verbatim: "Turned very greasy"

- A. Ill-defined disorder
- B. Unevaluable event
- C. Skin greasy
- D. Unevaluable reaction







Verbatim: "Deliberately took an overdose"

- A. Intentional overdose
- B. Overdose NOS
- C. Deliberate overdose
- D. Overdose





<u>Verbatim</u>: "Toddler accidentally took her mother's medication"

- A. Accidental overdose
- B. Accidental exposure to product by child
- C. Accidental drug intake by child
- D. Accidental ingestion





Verbatim: "Infection after surgery"

- A. Infection
- B. Postoperative wound infection
- C. Surgical wound infection
- D. Postoperative infection




Verbatim: "He sold his father's medication"

- A. Drug diversion
- B. Intentional product misuse
- C. Drug use for unapproved indication
- D. Intentional drug misuse



Verbatim: "Had MI"

- A. Myocardial infarction
- B. Ill-defined disorder
- C. MI
- D. Unevaluable event







Verbatim:

"Hypernatraemia (Serum sodium = 115 mEq/L)"

- A. Serum sodium abnormal
- B. Hypernatraemia
- C. Hyponatraemia
- D. Serum sodium decreased





Verbatim: "Took intramuscular drug by mouth"

- A. Wrong route of administration
- B. Drug administered via inappropriate route
- C. Medication error
- D. Intramuscular formulation administered by other route



<u>Verbatim</u>: "The doctor mistakenly prescribed the wrong drug; the pharmacist noticed the error before dispensing the drug"




- A. Wrong drug dispensed
- B. Medication error
- C. Intercepted drug prescribing error
- D. Intercepted drug dispensing error



<u>Verbatim</u>: Patient attempted to commit suicide by walking into the sea; unfortunately, he could swim

- A. Suicidal behaviour
- B. Attempted suicide
- C. Completed suicide
- D. Death






<u>Verbatim</u>: "Dose taken was below the minimum recommended dose in the product label"

- A. Underdose
- B. Drug administration error
- C. Accidental underdose
- D. Incorrect dosage administered



<u>Verbatim</u>: "After taking an antihistamine along with her prescribed proton pump inhibitor, a 53-year-old woman developed vertigo."

- A. Drug interaction NOS
- B. Vertigo subjective
- C. Vertigo
- D. Drug interaction





<u>Verbatim</u>: "The medication was stored at room temperature instead of in the refrigerator where it belonged."

- A. Incorrect storage of drug
- B. Improper storage of unused product
- C. Intercepted medication error
- D. Product storage error temperature too high



<u>Verbatim</u>: The 66 year old man died from a ruptured aortic aneurysm

- A. Aortic aneurysm rupture
- B. Ascending aortic aneurysm rupture
- C. Dissecting aortic aneurysm, ruptured
- D. Death
- E. A & D both






Quick Guess?

- Hippo tension
- Mousy feeling in chest
- Patient recently began new job where he works around chicken wings and barbecue sauce
- Loss of brain
- Spray it in the nose as much as you want and the Septum is gone
- Medication messed up with the brain
- Adult teeth came in three different colors yellow, green and white
- Husband had his uterus scrapped and frozen
- Death-worsened clinically by end of 4 hrs rx
- Even Need to spend more time with my wife (as the subject stated)













How is MedDRA Used for Analysis?

- MedDRA can be used to summarise large volumes of data
 - Standard approach is to list data at PT and SOC levels for overview
- Focused searches can be made using features of MedDRA
 - Searching for specific PTs
 - Summarising at HLT or HLGT levels
 - Using multiaxial links to group diagnoses with signs and symptoms
 - Selecting a set of relevant PTs which reflect the condition of interest
 - Using Standardised MedDRA Queries (SMQs) for signal detection
 - Customized search / Modified MedDRA Queries



More on SMQ and Data Retrieval?

- Documentation :
- SMQ Introductory Guide

https://www.meddra.org/how-to-use/support-documentation

- Processes:
- MedDRA Data Retrieval and Presentation: Points to Consider
 https://www.meddra.org/how-to-use/support-documentation
- Training:
- Face-to-Face Training MedDRA: Safety Data Analysis and SMQs
- Webinar
- Training Videocast

https://www.meddra.org/training/offerings



MedDRA Know more?

Visit: <u>www.meddra.org</u>



MedDRA Training

How to subscribe

Learn more

16 August 2019
Register for the
MedDRA & UMC
WHODrug User Group
Meeting

Bristol-Myers Squibb is hosting the next US Industry MedDRA User Group meeting on 3 October and the UMC WHODrug meeting on 4 October

15 August 2019 MedDRA v22.1 will be





Medical Dictionary for Regulatory Activities

Thank You!!

- anamika.dutta@meddra.org
- mssohelp@meddra.org



